Sugi Predict

Sugi Predict / Compounds / SCHEMBL1727101

SCHEMBL1727101

SCHEMBL1727101

Cc1ccc(OP(Oc2ccc(C)cc2)c2ccc(C)cc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACHE P22303 4/20 0.46
▸ TDP1 Q9NUW8 2/20 0.40
▸ CYP3A4 P08684 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ TEAD4 Q15561 1/20 0.39
▸ ALDH1A1 P00352 2/20 0.38
▸ POLB P06746 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ CA1 P00915 2/20 0.37
▸ CA2 P00918 2/20 0.37
▸ CA9 Q16790 2/20 0.37
▸ RELA Q04206 1/20 0.37
▸ DRD2 P14416 1/20 0.33
▸ DRD4 P21917 1/20 0.33
▸ DRD3 P35462 1/20 0.33
▸ WDR5 P61964 1/20 0.33
▸ KCNH2 Q12809 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28876309 0.89 LMNA (0.42) ACHETDP1CYP3A4TSHRTEAD4
SCHEMBL1726173 0.85 ACHE (0.46) ACHETDP1CYP3A4TSHRTEAD4
SCHEMBL130635 0.78 ACHE (0.55) ACHETDP1CYP3A4TSHRTEAD4
SCHEMBL7771299 0.76 ACHE (0.52) ACHETDP1CYP3A4TSHRTEAD4
SCHEMBL4809479 0.76 ACHE (0.52) ACHETDP1CYP3A4TSHRTEAD4
SCHEMBL8650801 0.76 ACHE (0.52) ACHETDP1CYP3A4TSHRTEAD4
SCHEMBL1727294 0.75 MAPT (0.45) TDP1TSHRALDH1A1POLBMAPT
SCHEMBL11078704 0.75 LMNA (0.42) ACHETDP1CYP3A4TSHRTEAD4
SCHEMBL389944 0.74 ACHE (0.44) ACHETDP1CYP3A4TSHRTEAD4
SCHEMBL1725482 0.74 ACHE (0.50) ACHETDP1CYP3A4TSHRTEAD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240002313-A1 [11C]-LABELED ACYCLIC RETINOID, CENTRAL NERVOUS SYSTEM ACTIVATOR, AND PRODUCTION METHODS FOR SAME NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY (JP) 2024-01-04 — — US disclosed
EP-4249058-A1 [11C]-LABELLED ACYCLIC RETINOID, CENTRAL NERVOUS SYSTEM ACTIVATOR, AND PRODUCTION METHODS FOR SAME National Center for Geriatrics and Gerontology (JP) 2023-09-27 — — EP disclosed
EP-3377596-A1 SELECTIVE HYDROGENATION USING A FLOW INDEX Chevron Phillips Chemical Company LP (US) 2018-09-26 — — EP disclosed
US-20180148260-A1 Selective Hydrogenation Using a Flow Index CHEVRON PHILLIPS CHEMICAL COMPANY LP 2018-05-31 — — US disclosed
US-9914676-B2 Selective hydrogenation using a flow index CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2018-03-13 — — US disclosed
US-20170349507-A1 Selective Hydrogenation Using a Flow Index CHEVRON PHILLIPS CHEMICAL COMPANY LP 2017-12-07 — — US disclosed
EP-3218104-A1 SELECTIVE HYDROGENATION CATALYST AND METHODS OF MAKING AND USING SAME Chevron Phillips Chemical Company LP (US) 2017-09-20 — — EP disclosed
US-9758446-B2 Selective hydrogenation using a flow index CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2017-09-12 — — US disclosed
EP-2403642-B1 METHODS OF USING A SELECTIVE HYDROGENATION CATALYST CHEVRON PHILLIPS CHEMICAL CO LP (US) 2017-08-02 — — EP disclosed
US-20170137346-A1 Selective Hydrogenation Using a Flow Index CHEVRON PHILLIPS CHEMICAL COMPANY LP 2017-05-18 — — US disclosed
EP-3144064-A2 SELECTIVE HYDROGENATION CATALYST AND METHODS OF MAKING AND USING SAME Chevron Phillips Chemical Company LP (US) 2017-03-22 — — EP disclosed
US-20160355449-A1 Hydrogenation Using Highly Selective Catalyst CHEVRON PHILLIPS CHEMICAL COMPANY LP 2016-12-08 — — US disclosed
WO-2016077445-A1 SELECTIVE HYDROGENATION CATALYST AND METHODS OF MAKING AND USING SAME CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2016-05-19 — — WO disclosed
US-20150197464-A1 Selective Hydrogenation Catalyst and Methods of Making and Using Same CHEVRON PHILLIPS CHEMICAL COMPANY LP 2015-07-16 — — US disclosed
US-8633127-B2 Selective hydrogenation catalyst and methods of making and using same CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2014-01-21 — — US disclosed
EP-2403642-A2 SELECTIVE HYDROGENATION CATALYST AND METHODS OF MAKING AND USING SAME Chevron Phillips Chemical Company LP (US) 2012-01-11 — — EP disclosed
WO-2010101736-A2 SELECTIVE HYDROGENATION CATALYST AND METHODS OF MAKING AND USING SAME CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2010-09-10 — — WO disclosed
US-20100228065-A1 Selective Hydrogenation Catalyst and Methods of Making and Using Same CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2010-09-09 — — US disclosed
US-5600034-A HEAT TREATING DIALLYL ETHERS IN PRESENCE OF CATALYST CONTAINING PALLADIUM AND PHOSPHORUS COMPOUNDS MITSUBISHI CHEMICAL CORPORATION (JP) 1997-02-04 — — US disclosed
US-5583271-A Method for continuously producing alkadienols MITSUBISHI CHEMICAL CORPORATION (JP) 1996-12-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240002313-A1 [11C]-LABELED ACYCLIC RETINOID, CENTRAL NERVOUS SYSTEM ACTIVATOR, AND PRODUCTION METHODS FOR SAME NR2E3, FABP7, RARB ACHE 20/4885TDP1 3661/4885CYP3A4 2009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.